Overview

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare plasma and intracellular pharmacokinetic parameters of raltegravir 800 mg administered once daily in HIV infected patients.

Phase:

Phase 4

Details

Lead Sponsor:

Germans Trias i Pujol Hospital

Collaborator:

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Treatments:

Raltegravir Potassium